<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208529</url>
  </required_header>
  <id_info>
    <org_study_id>CTX001-131</org_study_id>
    <secondary_id>2018-002935-88</secondary_id>
    <nct_id>NCT04208529</nct_id>
  </id_info>
  <brief_title>A Long-term Follow-up Study in Subjects Who Received CTX001</brief_title>
  <official_title>A Long-term Follow-up Study of Subjects With Î²-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRISPR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, observational study to evaluate the long-term safety and efficacy of
      CTX001 in subjects who received CTX001 in Study CTX001-111 (NCT03655678) or Study CTX001-121
      (NCT03745287).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">September 2039</completion_date>
  <primary_completion_date type="Anticipated">September 2039</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>New malignancies</measure>
    <time_frame>Signing of informed consent up to 15 years post CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New or worsening hematologic disorders</measure>
    <time_frame>Signing of informed consent up to 15 years post CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Signing of informed consent up to 15 years post CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs) occurring up to 5 years after CTX001 infusion</measure>
    <time_frame>Signing of informed consent up to 5 years post CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CTX001-related AEs</measure>
    <time_frame>Signing of informed consent up to 15 years post CTX001 infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb) concentration over time</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbF concentration over time</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of alleles with intended genetic modification present in peripheral blood leukocytes over time</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion dependent thalassemia (TDT) related transfusions for beta-Thalassemia subjects</measure>
    <time_frame>Signing of informed consent up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron overload as measured by liver iron concentration (LIC), cardiac iron concentration (CIC), and ferritin for beta-Thalassemia subjects</measure>
    <time_frame>From Day 1 up to 5 years post CTX001 infusion (for LIC and CIC) and up to 15 years post CTX001 infusion (for ferritin)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving iron chelation therapy over time</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe vaso-occlusive crises (VOC) events for severe sickle cell disease (SCD) subjects</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sickle cell disease (SCD) related transfusions for SCD subjects</measure>
    <time_frame>From Day 1 up to 15 years post CTX001 infusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Beta-Thalassemia</condition>
  <condition>Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>CTX001</arm_group_label>
    <description>All subjects who complete or discontinue the parent study (CTX001-111 or CTX001-121) after CTX001 infusion will be asked to participate in this long-term follow-up study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX001</intervention_name>
    <description>CTX001 infusion</description>
    <arm_group_label>CTX001</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who complete or discontinue the parent study (CTX001-111 or CTX001-121) after
        CTX001 infusion will be enrolled in the long-term follow-up study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects or legal representative or guardian (if applicable) must sign and date
             informed consent form (ICF)

          -  Subjects must have received CTX001 infusion

        Exclusion Criteria:

          -  There are no exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia University Medical Center (21+ years)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

